Compare Stocks

→ $25,000 into $109,616 in two months? (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPTI Optec International	$0.00	$0.00	$0.00 ▼ $0.00	$41K	N/A	41.09 million shs	16.50 million shs
PMN ProMIS Neurosciences	$1.95 -4.9%	$2.04	$0.95 ▼ $8.95	$36.98M	0.67	38,692 shs	3,356 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPTI Optec International	-5.41%	+29.63%	-7.89%	+218.18%	+775.00%
PMN ProMIS Neurosciences	-4.88%	+4.84%	+7.14%	-1.52%	-70.68%

He Is Giving Away Bitcoin (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPTI Optec International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	2.8771 of 5 stars	3.5	4.0	0.0	0.0	3.1	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPTI Optec International	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	3.00	Buy	$8.00	310.17% Upside

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPTI Optec International	N/A	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	$10K	3,697.96	N/A	N/A	$0.20 per share	9.75

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPTI Optec International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	-$13.21M	-$1.13	N/A	N/A	N/A	N/A	N/A	-141.23%	5/20/2024 (Estimated)

Latest OPTI, HEMO, and PMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	PMN ProMIS Neurosciences	N/A	-$0.09	-$0.09	-$0.09	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPTI Optec International	N/A	N/A	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPTI Optec International	N/A	N/A	N/A
PMN ProMIS Neurosciences	N/A	1.46	1.46

Ownership

Institutional Ownership

Company	Institutional Ownership
OPTI Optec International	N/A
PMN ProMIS Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
OPTI Optec International	50.34%
PMN ProMIS Neurosciences	10.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
OPTI Optec International	1	11.65 million	N/A	Not Optionable
PMN ProMIS Neurosciences	6	18.96 million	17.01 million	Not Optionable

OPTI, HEMO, and PMN Headlines

Source	Headline
	ProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93 msn.com - April 17 at 9:02 AM
	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS globenewswire.com - April 9 at 7:00 AM
	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April globenewswire.com - April 4 at 7:00 AM
	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights globenewswire.com - April 1 at 4:15 PM
	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio globenewswire.com - March 11 at 7:00 AM
	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference globenewswire.com - February 22 at 7:00 AM
	Researchers discover a promising compound to treat neuropathic pain interestingengineering.com - February 4 at 12:20 AM
	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine finance.yahoo.com - January 22 at 8:48 AM
	ProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transition finanznachrichten.de - January 3 at 9:13 AM
	BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN) markets.businessinsider.com - January 3 at 9:13 AM
	ProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officer markets.businessinsider.com - January 3 at 9:13 AM
	ProMIS Neurosciences, Inc. Announces Leadership Transition finance.yahoo.com - January 3 at 9:13 AM
	ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14 msn.com - November 14 at 7:10 PM
	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference finance.yahoo.com - September 6 at 3:28 PM
	ProMIS Neurosciences Inc. [PMN] Investment Appeal on the Rise knoxdaily.com - August 23 at 4:58 PM
	ProMIS Neurosciences scales 31% on $20.4M private placement msn.com - August 22 at 7:40 AM
	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing finance.yahoo.com - August 21 at 4:38 PM
	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights finance.yahoo.com - May 15 at 6:49 PM
	Closing Bell: Promis Neurosciences Inc down on Friday (PMN) theglobeandmail.com - May 6 at 8:15 AM
	Closing Bell: Promis Neurosciences Inc up on Thursday (PMN) theglobeandmail.com - April 27 at 10:10 PM
	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease finance.yahoo.com - April 25 at 5:52 PM
	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting finance.yahoo.com - April 24 at 8:50 AM
	Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN) theglobeandmail.com - April 19 at 1:59 AM
	Closing Bell: Promis Neurosciences Inc down on Monday (PMN) theglobeandmail.com - April 18 at 3:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks With Unusual Call Option Activity
March 26, 2024 1:10 PM
View 3 Stocks With Unusual Call Option Activity
Best Bear Market Funds: Top 3 Investment Options to Consider
March 27, 2024 10:58 AM
View Best Bear Market Funds: Top 3 Investment Options to Consider
Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
How and When to Roll Your Options Positions?
March 27, 2024 9:32 AM
View How and When to Roll Your Options Positions?
ASML Fires Warning Shot For Tech Investors
April 17, 2024 9:05 AM
View ASML Fires Warning Shot For Tech Investors

All Headlines

Company Descriptions

Optec International

OTCMKTS:OPTI

Optec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California.

ProMIS Neurosciences

NASDAQ:PMN

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial